1 Min Read
Laverock Therapeutics has been awarded more than £2.2m in grant funding to support development of its gene-control platform and expand research into therapeutic areas beyond oncology. The biotechnology company said the funding will support further development of its single-cell and artificial intelligence (AI)-powered technology, which is designed to create disease-responsive advanced therapies. One project will […] The post Laverock secures funding for gene-control platform development appeared first on Pharmafile.
Work & Theory on June 6, 2026
Uncategorized